BioNTech (ADRs Termine: Hier finden Sie die Termine-Seite für den Wert BioNTech (ADRs Yes. Antwort auf Beitrag Nr. 2020 Guidance: As a result of increased spending related to BNT162, BioNTech now expects net cash used in operating activities to be between €450M and €600M. AlzChem Group AG: Starke Performance im Q4, EBITDA 2020 +7,4 % Umsatz steigt leicht auf 379,3 Mio. And Ozlem Tureci will provide some pipeline updates. Cumulative Growth of a $10,000 Investment in Stock Advisor, BioNTech SE (BNTX) Q4 2019 Earnings Call Transcript @themotleyfool #stocks $BNTX, BioNTech SE (BNTX) Q3 2020 Earnings Call Transcript, BioNTech SE (BNTX) Q2 2020 Earnings Call Transcript, BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Can you tell us what is the scientific rationale of using it in infectious disease vaccine? I will take that one. Seit Dienstag … So thank you. Just can you — since biopsy volumes are down, I'm just curious if the enrollment criteria that you have in place enables use of archival tissue and how you're collecting biomarker data for your oncology trials, collecting and processing? Now on Slide 12, I want to give some additional detail on two of our most advanced immuno-oncology programs, BNT111 and BNT122. Disclosures and News. In terms of the manufacturing at risk part of your question, I think, it was our strategy from the beginning to try to get a global consortium in place. And this is, of course, an exciting opportunity to elaborate and to test in a setting where the manufacturing of the sufficient scale of vaccine could be a challenge. BioNTech SE Regarding BNT162, that's the COVID-19 vaccine, among SME and proteins, what could be your target? With regards to your publication that you mentioned in your prepared remarks, as expected, in the second half of the year of Phase I data for melanoma, can you give us an idea of what level of detail you expect to have in that article? Yes, I can take this one. And I was wondering if you could comment on modifications to your clinical trials or enrollment criteria. Before I move on. The short message is that we do expect some impact to the timelines we have previously communicated. As shown on Slide 9, while our review of the impact is ongoing, we are developing and implementing the three-point plan to manage the still evolving disruptions that the pandemic is creating. So the archival tissues for development of oncology trial. Thank you very much. Therefore, continuing the activities to progress toward initiation of these trials is a key priority for the company. mRNA vaccines have been shown to be highly immunogenic and induce neutralizing antibodies as well as T cell responses. And you may have heard that some regulatory authorities give guidance in particular for deviations, how to document them, for example, in order to ensure that they can then be addressed by regulators appropriately, given the situation, the entire clinical trial landscape is in. Thanks for the question. So first of all, all of our formats induce in the combination with the formulation, which we are using, CD4 as well as CD8 T cell responses. You refer to the PD-L1/4-1BB dual body, which we are developing in operation with our partner, Genmab, we are pretty advanced in our dose escalation. BB BIOTECH Termine - hier erhalten Sie eine Übersicht über alle anstehenden und vergangenen Termine wie Quartalszahlen und Hauptversammlung von BB BIOTECH. Thank you for today's call, and we look forward for meeting you in near future. Please go ahead. Außerdem … We had also the other companies you are referring to have with the regulators and the data which we can all present from our trials. Eligible patients for dose titration have metastatic castration-resistant prostate cancer. And do you think titer of neutralizing antibodies can serve as surrogate clinical efficacy endpoint in COVID-19 vaccine development? I will now move to Slide 11 and provide some quick updates on our preclinical pipeline. And are you thinking about receptor binding domains? Lesen Sie jetzt die brandaktuelle Prognose! Just a few weeks ago, we signed a letter of intent with Pfizer regarding development of BNT162 outside of China and expect to provide more details of the financial terms behind our collaboration soon. BIONTECH AKTIE TERMINE Terminart Schätzung EPS Info Datum Quartalszahlen 0,1034 EUR Q4 2020 06.04.2021 (e)* Quartalszahlen 1,3390 EUR Q1 2021 18.05.2021 (e)* Quartalszahlen … BioNTech ended the third-quarter 2020 with cash and cash equivalents of EUR 990.5 million or $1,159.7 million, so that is $1.2 billion. I'll start with some detail on the effects of the coronavirus pandemic on the timing of our clinical trials. And then separately or along the same sort of lines, how are you thinking about antibody-dependent enhancement? To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. And I think more broadly, where is the ideal setting for a personalized cancer vaccine? And we see minimal differences in COVID variance isolated in different regions of the planet. Consistent with our stated objectives, we have increased the number of product candidates in clinical testing from seven to 10 since the completion of our IPO in October last year and have announced our intention to initiate multiple late-stage studies over the next 12 months. T: +49 6131 9084-0. Melden. Sure. The increase was primarily due to an increase in headcount and higher expenses regarding our collaboration projects. And then on oncology, you've talked a lot about delays. BioNTech meldet Quartalszahlen: Der Wecker für die Aktie bleibt (noch) stumm Mit der Entwicklung im ersten Quartal 2020 sieht sich die Mainzer BioNTech im Rahmen der eigenen Planungen. We expect the interim data in 2021 to include top line efficacy and safety data as of the interim date. But it is clearly our vision to have sufficient capacity to deliver to hundreds of million individuals doses of vaccine in a reasonable time period. BioNtech Aktionäre - WAHNSINNIGE BÖRSEN-RALLYE - der Grund ist erstaunlich! Anfang März 2020 gab BioNTech bekannt, einen Impfstoff zur Immunisierung und Prävention von COVID-19-Infektionen zu entwickeln. BIONTECH (ADRS) AKTIE TERMINE Terminart§Schätzung EPS Info Datum Quartalszahlen§-0,1715 EUR Q4 2020 06.04.2021 (e)* Quartalszahlen§1,7343 EUR Q1 2021 18.05.2021 (e)* Ob Quartalszahlen von DAX Unternehmen wie Wirecard, Deutsche Bank, SAP oder Daimler oder Quartalszahlen von US Unternehmen wie Amazon, Tesla, Apple oder Netflix – in unserer großen Liste der Quartalsberichte 2021 sehen Sie, wann und zu welcher Uhrzeit ein Unternehmen an der Börse Quartalszahlen veröffentlicht und wie hoch der erwartete bzw. Wondering, if you could provide some color on your conversations and maybe your strategy on potentially manufacturing at risk? First, we still intend to initiate Phase II trials for BNT111, BNT113 and the iNeST program, as originally planned. 07.08.2020 - Die BioNTech SE (ISIN: US09075V1026)-Aktie ist in Kursregionen vorgestossen, wo die Märkte - auch wenn deutlich unter den gesehenen Spitzen bei 10 Overall, as coronavirus situation remains dynamic, we will continue to monitor the situation as it evolves. We have partnered with Pfizer for worldwide development of the vaccine and have also established a strategic alliance with Fosun to develop the vaccine in China. You mentioned that you were working with the German, Chinese and U.S. governments. We are advancing along with our pharmaceutical collaborator about pipeline of first-in-class immunotherapies for the treatment of cancer. … This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. Furthermore, mRNA vaccines are well-defined biopharma particles with high-purity and are animal material-free. In January, we announced entry into a definitive merger agreement under which BioNTech would acquire Neon in an all-stock transaction. Quartal 2020 52.7 KB. And would it be in the late-stage, more bulky, solid tumors or perhaps in earlier settings? The first patient has been dosed in the reduced Phase I/II study, evaluating the safety and recommended Phase II dose of BNT321 in patients with pancreatic and above CA-19-9 positive malignancy. Can you just give us a sense of where you are in terms of dose escalation for BNT311? Operations were strong in 2020, with full-year BP-operated refining availability of 96% and Upstream plant reliability of 94%. Early in January, this year, we announced the signing of a merger agreement and our offer to acquire Neon Therapeutics, which, if Neon shareholders vote in favor of the merger and the other conditions to closing are met, will expect to bring us some exciting new pipeline candidates in cell therapy space. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. Die Eckdaten von Evonik zum dritten Quartal liegen teils über den Erwartungen. mg90: @Diletant 15.12.20 16:34 #25894. First, however, I wanted to highlight Ryan's appointment as chief strategy officer. You are, therefore, cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this conference call and webcast. And this is a way forward approach. We have built a broad suite of novel therapeutic platform to exploit the full potential of the immune system. Operator? And we are in the next 12 months, we are going to publish a number of collaborative studies with Genentech showing how next-generation vaccine could look like. Hier ist Benzinga's wesentlicher Leitfaden für den Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. Aber 2021 sieht das dann schon anders aus, wenn die ersten größeren Impfstoffdosenmengen geliefert und verkauft werden. Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst. Sean, do you want to say a few words about our recently announced collaborations for our COVID-19 vaccine? Intel Data Center Group in Q4/2020 (Bild: Intel) Für das erste Quartal erwartet Intel einen Umsatzrückgang auf 17,5 Milliarden US-Dollar. That question comes from the line of Arlinda Lee from CG. Of course, based on the situation, we can generate safety and activity efficacy and effectivity data in different regions of the world. And finally, progress has been made in our clinical program for BNT321. We believe that the trial of BNT111 and BNT113, these are our FixVac products for melanoma and for HPV-positive cancers, have the potential to be registrational studies. Here, the data we will publish is data that comes from our Lipo-MERIT trial of a dose escalation, dose expansion trial with our melanoma FixVac in heterogeneous population of patients with advanced melanoma and what we will publish. Go to Web- and Download-Version of the Annual Report 2020 View the recording of our Annual Press Conference (March 16, 2020) Go to Documents (Overview Page) View the Press Release . We expect to conduct a global development program spanning Europe, United States and China. OK. And another question regarding the RNA format and also the delivery formulation. Q2. Sierk Poetting will then review our financial results. In general, the agency also enables non-in-person meeting, personal phone conferences. But also some safety and activity data. And therefore, also based on preclinical data that we have seen for COVID-19, which are encouraging. I will start with a few introduction remarks followed by an update of our significant efforts to address the COVID-19 pandemic that is having a severe impact around the globe. Market data powered by FactSet and Web Financial Group. Thanks for the interesting question. We are on track in the development of our vaccine approach and expect a timely start of the first clinical trial in Germany in the second half of 2020. Manufacturing remains a key strategic priority for us as we advance our pipeline of product candidates toward the market. Sure. Safety performance was also strong with both tier1/tier2 process safety events and reported recordable injury frequency significantly lower than in 2019. And I think that's so important for your early Phase I trials. Yes. Slides 2 and 3 provides legal disclosures related to the pending acquisition of Neon Therapeutics. Seitdem sind sie schon mehr als 145 % (09.03.2021) gestiegen. How regulatory authorities see, for example, potential deviation? ... Q4 2020… The data was previously expected to be presented at CIMT Annual Meeting, scheduled for May. BIONTECH (ADRS) AKTIE TERMINE Terminart§Schätzung EPS Info Datum Quartalszahlen§-0,1715 EUR Q4 2020 06.04.2021 (e)* Quartalszahlen§1,7343 EUR Q1 2021 18.05.2021 (e)* Quartalszahlen§2,5251 EUR Q2 2021 17.08.2021 (e)* Quartalszahlen§3,7441 EUR Q3 2021 17.11.2021 (e)* On July 27, 2020, BioNTech announced the closing of an underwritten offering of 5,500,000 American Depositary Shares (“ADSs”), each representing one of BioNTech… Q2 2020 Financial Report 314.6 KB. BNT112 is our FixVac candidate for the treatment of prostate cancer. Das EPS lag bei 0,110 USD. And can you maybe discuss at a high level, how your vaccine approach might be differentiated? [Operator instructions] I must advise you this call is being recorded today, Tuesday, the 31st of March, 2020. We have built a growing number of programs targeting infectious disease. We also recently announced our strategic alliance with Fosun Pharma, our first strategic collaboration in Asia, to jointly develop BNT162 in China. First, for our FixVac portfolio, BNT116 has been added to our product portfolio and is currently in preclinical development for non-small cell lung cancer. And can you help us understand how you're thinking about durability protection with your vaccine and your hypothesis on necessary boost schedule? We work, in fact, with archival tissue from this patient. Would you like to make some closing remarks? OK. Makes sense. And also, you're doing a lot of biomarker studies. Now I would like to summarize our financial results that are shown on Slide 13. BioNTech beabsichtigt, Ende April 2020 die klinische Studie des Produktkandidaten BNT162 ein möglicher first-in-class mRNA … We have also increased our pharma partnerships for the recent expansion of our Pfizer collaboration and the announcement of our first Asian partnership, a strategic alliance with Fosun Pharma. Turning to Slide 8. So we are using here a vaccine with an inherent adjuvant effect. Crown Capital Securities is an Independent Financial Service firm established in 1999 by like-minded entrepreneurs for entrepreneurs. The next question today comes from Navin Jacob from UBS. Regarding the iNeST Phase II trial in first-line melanoma, we still plan to provide detailed interim data in 2021 and an enrollment update in H2 2020. So a couple of questions. So we have, of course, ongoing trials with our actually third-generation messenger RNA platforms running with in collaboration with Genentech. Pfizer Inc. has sequestered a team of nearly 75 scientists and engineers at its Kalamazoo facility to design and build a manufacturing line to produce a vaccine for COVID-19 as soon as the fourth quarter — a huge investment to make a product that has yet to be proven to work. Yes. Following a strong and productive 2019, we have several important milestones ahead of us in 2020, as shown on Slide 14. And also for our Influenza program and our Rare Disease program. Our mRNA vaccine for COVID-19 exploits a highly potent lipid nano particulate or LNP, messenger RNA vaccine potent. BIONTECH (ADRS) AKTIE TERMINE Terminart§Schätzung EPS Info Datum Quartalszahlen§-0,1715 EUR Q4 2020 06.04.2021 (e)* Quartalszahlen§1,7343 EUR Q1 2021 18.05.2021 (e)* Quartal 2020 344.3 KB. Am Mittwoch, dem 14. We expect BNT111 and 114, the TNBC and melanoma FixVac trials to be less affected given that these trials are near completion of enrollment. Other COVID-19 vaccines that we've heard about from other companies that have been commented, they've talked about, and they've talked about timelines and talked about things like 12 to 18 months in a situation like this, potentially get it from start to finish. Sierk Poetting -- Chief Financial and Operating Officer. BioNTech SE (NASDAQ:BNTX)Q4 2019 Earnings CallMar 31, 2020, 8:30 a.m. Thanks, Sean. The next question today comes from the line of Tazeen Ahmad from Bank of America. Please go ahead. In studies, for someone to test whether the patient has a certain marker, which is stable. Biontech & MRNA: Revolution in der Pharmaindustrie: Ich öffne diesen Thread, um über das Unternehmen Biontech, die MRNA Technologie im Kontext der Pharmaindustrie zu diskut... X-DAX: 14.569 +0,17%: Dow Jones: 32.779 +0,90%: L-TecDAX: 3.344 -0,55%: Dollarkurs: 1,195 -0,01%: Aktien; News; Forum; Zertifikate; Hebelprodukte; Devisen; Rohstoffe; Fonds; ETFs; Zinsen; Wissen; Depot . Evidenced in the preclinical settings, we have published data showing that this is the case for HIV and this is the case for influenza vaccine. Unilever Aktie - Quartalszahlen Q4 2020 in der Analyse - Kurssturz = Einstiegschance ? Next, on your COVID vaccine, can you talk about your self-amplifying mRNA platform in the context of your vaccine? tatsächliche Gewinn je Aktie (EPS) … Google mal nach Quartalszahlen Biontech.Da werden die Termine angezeigte . Euro (+7,4 %) … BIONTECH AKTIE TERMINE Terminart Schätzung EPS Info Datum Quartalszahlen 0,1034 EUR Q4 2020 06.04.2021 (e)* Quartalszahlen 1,3390 EUR Q1 2021 18.05.2021 (e)* Any color on what those tweaks are? PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS Upjohn Business(1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted(2) Results Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclude Upjohn(1), Reflect 3% Operational Growth; When the Impact from Consumer Healthcare(1) and the … But one, it will bring us some exciting preclinical programs, including NEO-PTC-01, a personalized neoantigen-targeted T-cell therapy candidate, consisting of multiple T cell populations that target the most therapeutic relevant neoantigen from each patient's tumor. And I have one follow-up. First, an update on BNT111, our FixVac candidate for the treatment of advanced melanoma. I have a few questions. The recently initiated programs such as BNT112, which is prostate cancer FixVac, are more likely to be affected by these delays. And as it relates to a potential for registrational study, what in your discussions with FDA gives you confidence that you would be able to potentially use the next study as registrational versus having to do a full Phase III? Actual results could differ from those we currently anticipate. Thank you, Ozlem. Quartalszahlen: Hier finden Sie alle Veröffentlichungstermine der Quartalszahlen im Überblick. And so we are continuing to evaluate how best to scale up the manufacturing effort and fund it through those relationships with existing partners and also potential new sources of capital. In the expansion part, also patients with newly diagnosed, high-risk, localized prostate cancers are eligible and will be treated with BNT112. So this will need to be really worked out in the ongoing discussions. The transaction remains subject to a vote of Neon shareholders, which we expect to take place during the second quarter. For BNT111, our melanoma FixVac, we expect data from our Phase I trial in advanced melanoma to be published in the medical journal in late H1 2020. Delayed start of first-in-human Phase I studies may occur for our RiboMabs program, BNT141 and 42; our RiboCytokines program, BNT151, 52 and 53; and our TLR7 agonist program, BNT411. Hier ist Benzinga's Vorschau auf die BIONTECH (ADRS) Termine - hier erhalten Sie eine Übersicht über alle anstehenden und vergangenen Termine wie Quartalszahlen und Hauptversammlung von BIONTECH (ADRS). 11.08.2020 12:50 Uhr - Autor: Michael Barck auf Twitter BioNTech hat heute Mittag die mit Spannung erwarteten Quartalszahlen vorgelegt. BioNTech SE An der Goldgrube 12 55131 Mainz Germany. Thank you for the question. I now hand the call over to Ugur Sahin, BioNTech's CEO. Q1. And we see with this type of vaccine regardless of the epitopes that we are using long-lasting immune responses. As I mentioned earlier, BNT211, our CAR-T program targeting solid tumors is on track to go in the clinic in summer this year. For now, we maintain timing guidance for our COVID program, BNT211. As I mentioned earlier, we have had further discussions with regulatory authorities regarding next steps and the design of a registrational trial. Good morning guys and thank you for taking my questions. In response to the coronavirus outbreak, we continue to monitor the potential impact to our supply chain and manufacturing operations, which includes mRNA manufacturing for FixVac and iNeST platform products as well as our CAR-T manufacturing side. What data you need to see to ensure that that won't be an issue? So the development of our COVID vaccine is based on our in-house platforms. For BNT122, we disclosed with Genentech that two additional Phase II clinical trials in the adjuvant setting are planned for initiation in 2020. Do you think that's a kind of a realistic expectation for your program as well? ma_ko: @Warli 15.12.20 16:37 #25895. Together with Fosun Pharma, we intend to conduct clinical trials in China, leveraging our mRNA vaccine technology and manufacturing and Fosun's extensive clinical development, regulatory and commercial capabilities in the country. We've heard some people speculate that coronaviruses may need a T cell immunogenistic response in addition to an antibody, and you've talked mostly about antibody response. Genentech highlighted iNeST potential to provide a personalized cancer vaccine for a broad range of cancer patients. I guess, to start, your COVID-19 program, BNT162, what are the gating factors to getting this product into the clinic? Der Umsatz von 2,92 Milliarden Euro (Vorjahr: 3,23 Milliarden Euro) trifft den Konsens. handling or other issues:service@biontech.de, For any other questions, please Sylke Maas -- Vice President, Investor Relations, and business Strategy. So actually, we have a set of mechanistic data that the different platforms, which we are using, all produce different levels of Th1 responses. Thank you very much. The firms’ founding partners were made of a group of financial advisors, who were looking to build a broker dealer that emphasized a philosophy, which is based on long lasting personal relationships and family values. Daina Graybosch -- SVB Leerink -- Analyst. We have three messenger RNA platforms, which are currently exploited for development of COVID vaccines, exploiting different epitopes. We look forward to updating investors and other stakeholders throughout 2020. With regard to the biomarker strategy, of course, we need to evaluate antibody responses before vaccination and after vaccination. We look forward to closing the acquisition and beginning the integration process. Ryan? Thanks, Ugur. I will then make a few closing remarks on the outlook for 2020 before opening up the call for questions. Net loss was EUR 58.2 million for the fourth quarter of 2019 compared to a net loss of EUR 1.5 million for the prior year period. Now turning to our intratumoral immunotherapy program, partnered with Sanofi. We will now take any questions you may have. Yes, I think, there is a series of publications showing the different type of infiltrates, including infiltrates with dendritic cells and B cells are associated with the improved prognosis and responds to a checkpoint location. Fosun Pharma has the rights to commercialize vaccine in China and will pay BioNTech up to USD 135 million, that's EUR 120 million, in upfront and potential future investment and milestone payments. Im letzten Jahr hatte Arcos Dorados A … OK. I would like to point out that we expect to start a Phase I/II trial using CARVac BNT211 in Claudin 6-positive solid tumors.
Sansibar Urlaub Flugzeit, Melia Hotel Zanzibar Prices, Aquaman 4k Review, Bachelor 2021 Wer Gewinnt, Hoffnungstaler Stiftung Lobetal Organigramm, Verkehrsunfall B38 Heute, Aroosha Name In Urdu, Haushalt Outlet Hamburg, Geschichte Dakar Senegal,